-1. PYLARIFY (piflufolastat F18) injection. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. 47 on an adjusted basis, an increase of 48% over the prior-year quarter. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. PYLARIFY identifies PSMA, the. According to Evaluate, doctors prescribing Pluvicto are abandoning Novartis' own. “This. LNTH-1095 (also known as MIP-1095) is a small molecule PSMA-targeted 131 I-based radioligand therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC) which combines a PSMA-targeted ligand, LNTH-1095, with the beta-emitting radioisotope 131 I. Lantheus Receives U. About Lantheus With more than 65 years of experience in delivering life. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. Lantheus has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. Syntermed announces its appointment by Lantheus Holdings, Inc. 37, while. Pylarify. Lantheus’ product, PYLARIFY, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. ATLANTA, March 31, 2022 /PRNewswire-PRWeb/ -- Syntermed is proud to. 7 million in the prior year period ; GAAP fully diluted net income per share of $0. Lantheus Reports Second Quarter 2023 Financial Results. PYLARIFY is used along with positron emission tomography (PET) imaging for men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. , June 12, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Billerica, MA 01862 . [Image courtesy of Lantheus] Lantheus is a developer of AI-powered diagnostic and therapeutic products. , May 23, 2023 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. 2 million for the third quarter 2022, compared to GAAP net loss of $13. com. The system is intended to be used with images acquired using nuclear medicine (NM) imaging using PSMA PET/CT. 37. Since then, Lantheus' sales have more than doubled. (“the Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence. 7 million is being distributed to the holders. NORTH BILLERICA, Mass. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12,. by year endNORTH BILLERICA, Mass. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer May 27, 2021 PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly availableLantheus delivered a BIG and welcome beat-and-raise quarter and shares were up as much as +20%, poking their nose over $71. On-site plant will produce. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100. Image source: The Motley Fool. PYLARIFY® [package insert]. S. In the U. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. PYLARIFY ® (piflufolastat F 18) injection (also known as 18 F-DCFPyL or PyL) is a fluorinated small molecule PSMA-targeted PET imaging agent that enables visualization of lymph nodes, bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. 4% from the prior year period ; GAAP net income of $61. United States of America . “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. Clinical correlation, which may include histopathological evaluation of the suspected prostate cancer site, is recommended. The Lantheus Protocol: Pylarify Growth May Slow The outlook from management for Pylarify growth was not what analysts -- who are are modeling this product out 2-3 years -- were expecting. Lantheus provides a broad portfolio of products, including PYLARIFY ® (Piflufolastat F18), a PSMA PET imaging agent for the. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. 8 million, compared to a loss of $21. 646-975-2533. 8 billion tied up in biobucks. It was the Progenics deal that took Lantheus into radiotherapeutics, though at the time the $400m move was not especially well received. Each milliliter contains 37 to 2,960 MBq (1 to 80 mCi) piflufolastat F 18 with ≤0. “2022 was an outstanding year for Lantheus, led by the success of PYLARIFY and expansion of our Radiopharmaceutical Oncology pipeline. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. With 3 million men living with prostate cancer and more than 18. LNTH is scheduled to release third-quarter 2023 results on Nov 2, before the opening bell. PYLARIFY® FOR PCa IMAGING; EFFICACY AND SAFETY. PYLARIFY will be available immediately to imaging centers in parts of the mid- Atlantic and southern regions and is expected to be broadly available throughout the U. “We successfully launched PYLARIFY, which we believe is the best-in-class PSMA PET imaging agent for prostate cancer, maintained our revenue growth and. About Lantheus With more than 65 years of experience in delivering life. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer. The Pylarify AI system is a deep learning algorithm that allows physicians to. DULLES, Va. 29. 4 million in revenue, up 25% year over year, and a net loss of $11. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. GAAP. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States . The Company’s second quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. S. Lantheus Announces Presentations Featuring PYLARIFY AI at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting June 12, 2023 BEDFORD, Mass. Hours: 8:30 am to 8:00 pm ET, Monday to Friday. B Riley has resumed coverage of Lantheus Holdings (NASDAQ:LNTH) with a buy citing the company's growth trajectory due to the the launch of Pylarify, a prostate-specific membrane antigen (PSMA. Contact information For media. Comparison of Gallium-68 and Fluorine-18 imaging characteristics in positron emission. 4% from the prior year period. Pylarify is labeled with F-18 and homes in on PSMA, a protein that is overexpressed on the surface of more than 90% of. 3 million for the second quarter 2023. (LNTH) CEO Mary Anne Heino on Q2 2021 Results - Earnings Call Transcript. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men. 52%) were up 21. PYLARIFY uptake is not specific for prostate cancer and may occur with other types of cancer as well as non-malignant processes and in normal tissues. S. and EXINI Diagnostics AB. NORTH BILLERICA, Mass. patents apply to our products: DEFINITY ® /DEFINITY. S. For $260m Lantheus secured rights to Point’s two most advanced radioligand therapeutic projects, one of which concerns prostate cancer and hits PSMA – the target for Pylarify and for two Lantheus development-stage therapeutics. 5 million for the first quarter 2023. Lantheus has been on a revenue growth spurt in recent quarters, boosted by Pylarify. Melissa Downs Senior Director, Corporate Communications 646. com. 9, 2020-- Lantheus Holdings, Inc. 9 million for the first quarter 2022, representing an increase of 125. We have been thrilled with the response to PYLARIFY in the prostate cancer community, said Mary Anne Heino, President and Chief Executive Officer of Lantheus. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 [email protected] has multiple products on the market with two standouts driving the most growth with Pylarify and Definity. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. ir@lantheus. Food and Drug Administration (FDA) for Pylarify (F-18 DCFPyL), a PET radiopharmaceutical designed to target prostate-specific membrane antigen (PSMA). 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Please enter your ZIP code to locate the nearest imaging site that offers PYLARIFY®. Lantheus Holdings, Inc. “Lantheus delivered another strong quarter and full year, highlighted by revenue performance which increased 38% and 25%, respectively,” said Mary Anne Heino, President and CEO. BEDFORD, Mass. LNTH is expected to report second-quarter 2022 results on Jul 27. 4 million in the prior year period ; GAAP fully diluted net income per share of $0. , Nov. Our presentations at EANM highlight new data on the clinical utility of our artificial intelligence solution to assess response to prostate cancer therapy,” said Etienne Montagut , Chief Business Officer, Lantheus . 8M of net sales while cardiovascular ultrasound enhancement. PYLARIFY® CODING AND BILLING GUIDE | PYLARIFY® Reimbursement Hotline: 844-339-8514 PYLARIFY® and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. Eastern Time. NORTH BILLERICA,. – Paul Blanchfield, Chief Commercial Officer at Lantheus. PYLARIFY AI is the first and only FDA-cleared Artificial Intelligence-Enabled PSMA – a truly game-changing product. Follow. Welcome to the Lantheus Third Quarter 2023 Financial Results. May 4, 2023 at 7:00 AM · 10 min read. BEDFORD, Mass. 28, 2021 2:48 PM ET Lantheus Holdings, Inc. 9% Sodium Chloride Injection USP. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected. , a Lantheus company . diagnostic radiopharmaceutical. Lantheus Announces Presentations Featuring PYLARIFY® (Piflufolastat F18), PYLARIFY AI™ and NM-01 (PD-L1 Imaging) at the 2022 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting May 26, 2022 at 8:00 AM EDT PDF Version Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; PYLARIFY AI™, an artificial intelligence platform that assists in the. Además del éxito de PYLARIFY, Lantheus también destacó oportunidades de crecimiento en el tratamiento del cáncer de próstata con su producto PNT2002. 9 mg ethanol in 0. The Company’s third quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. In the U. BEDFORD, Mass. S. and EXINI Diagnostics AB. 2% for the week as of Friday afternoon,. 1 million for the second quarter 2023, compared to GAAP net income of $43. , Nov. Lantheus Holdings. , Nov. Quote. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent. 4% from the prior year period; GAAP net income of $43. , May 28, 2021 /PRNewswire/ -- SOFIE, an established Radiopharmaceutical Contract Manufacturing Organization and GMP radiopharmacy network, will be commercially. PYLARIFY® (piflufolastat F 18) Injection Indication PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:. 31 Mar, 2022, 09:00 ET. , Sept. 2. LNTH earnings call for the period ending June 30, 2021. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to expand its portfolio of commercial and clinical-stage radiopharmaceutical assets. 3% from the prior year period. PDF. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. S. 331 Treble Cove Road . As a leader in the development, manufacture and commercialization of pioneering diagnostic and therapeutic products, we’re determined to Find, Fight and Follow ® a broad range of diseases. On the call, management stated that PYLARIFY and DEFINITY enabled Lantheus to invest in its business to continue to. NASDAQ | LNTH (Common Stock) Data provided by Nasdaq. 5 million, representing 61. NORTH BILLERICA, Mass. “The data we presented at ASCO GU emphasize the clinical utility of piflufolastat F 18 to. , VP, Medical Affairs E. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. Lantheus Announces Updates to the NCCN Guidelines for PSMA PET Imaging for Prostate Cancer. Progenics Pharmaceuticals, Inc. The Lantheus Protocol: Pylarify Growth May Slow. For International Transportation Emergencies Call CC-BY-4. com. S. 61 for the second quarter. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. COMPANY IDENTIFICATION: Progenics Pharmaceuticals, Inc. For more information, visit Contacts: Mark Kinarney Vice President, Investor Relations 978-671-8842 ir@lantheus. An FDA-cleared medical device software, PYLARIFY AI V1. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a technetium-based generator. NORTH BILLERICA, Mass. with suspected recurrence based on elevated serum levels of prostate-specific antigen (PSA) level. 0. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions. 6 million for the fourth quarter of 2021, representing an increase of 103. While the company generated $527M in revenue from Pylarify, revenue from its other radiopharmaceutical oncology products reached $4. PYLARIFY PSMA - Where and when. BEDFORD, Mass. PYLARIFY (piflufolastat F18) injection . Melissa Downs Senior Director, Corporate Communications 646. Lantheus’ product, PYLARIFY ® (piflufolastat F 18) injection, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Lantheus provides a broad portfolio of products, including PYLARIFY ® (Piflufolastat F18), a PSMA PET imaging. Outside U. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. S. It will need to spend additional. S. 01. 66 from the prior year period. 1. 4 million in the prior year period ; GAAP fully diluted net income per share of $0. 5 million, representing 61. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging. Lantheus Holdings, Inc. com. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. Lantheus says its technology can help improve the management of prostate cancer patients. Lantheus Announces Presentations Featuring PYLARIFY AI™ at the 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. Before that Lantheus, which has operated since the 1950s, relied on established businesses in microbubbles and spect imaging. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY®, a PSMA PET imaging agent. While the company generated $527M in. 2 million for the fourth quarter and full year 2021, representing an increase of 37. 8% from the prior year period; GAAP net income of $94. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. Leading the way for Lantheus is PYLARIFY, which delivered sales of $210. Senior Director, Investor Relations. com. 3% over the prior year. Eastern, Monday - Friday © 2023 Lantheus. • Assay the dose in a suitable dose calibrator prior to administration. “Lantheus is leading the way in harnessing the power of AI and machine learning technologies, together with our game-changing PSMA-targeted PET imaging agent PYLARIFY, to potentially transform. The Company updates its guidance for the first quarter and full year 2023 is as follows: PYLARIFY revenues in 1H23 were $405m - up 82% year-on-year - so it seems clear that PYLARIFY revenues have substantially more growth potential - Lantheus' guidance for total revenues in 2023. February 16, 2023 at 8:30 AM EST. “PYLARIFY AI is the first and only FDA-cleared medical device software that offers a standardized platform for quantifying PSMA PET/CT images,” said Mary Anne Heino, President and Chief Executive Officer of Lantheus. Lantheus has Pylarify, a Flourine-18 isotope radioimaging product that selects patients for PSMA-targeted RLT. In 2023, PYLARIFY, the #1 PSMA PET imaging agent and DEFINITY, the #1 ultrasound enhancing agent, will continue to deliver value for our patients, healthcare professionals, employees, and shareholders. EMERGENCY PHONE: CHEMTREC 1-800-424-9300. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of. PYLARIFY –Prostate Cancer Franchise Overview Paul Blanchfield, Chief Commercial Officer Etienne Montagut, Chief Business Officer Aseem Anand, VP of Digital Solutions PYLARIFY Key Opinion Leader Panel Moderator: Bela Denes, M. The program is available to HCPs who have completed the PYLARIFY® Reader Training. Lantheus Holdings, Inc. PYLARIFY AI is an FDA-cleared artificial intelligence platform developed to assist in standardized quantification of PSMA PET/CT scans. 3. PYLARIFY® CODING AND BILLING GUIDE | PYLARIFY® Reimbursement Hotline: 844-339-8514 PYLARIFY® and the associated services provided in a physician office are billed on the CMS-1500 claim form or its electronic equivalent. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced PYLARIFY AI data will be presented at the. Email: cspyl@lantheus. 37, surpassing the consensus of $0. 4% from the prior year period. S. Phone: 1-800-964-0446. PYLARIFY® Peer-to-Peer Reader Assistance Program is a complementary program to the PYLARIFY® Reader Training that provides guidance and assistance to healthcare providers on how to accurately read and interpret PYLARIFY® scans. NORTH BILLERICA, Mass. Lantheus market research and analysis with ordering physicians, NCCN, ACS, UpToDate, SEER. PYLARIFY AI™ (aPROMISE) is the only deep learning enabled FDA-cleared medical device software to offer standardized PSMA PET reporting on PSMA PET/CT images, including those achieved using. Lantheus will fund the all-cash license of exclusive worldwide rights, excluding certain territories 1, for PNT2002 and PNT2003 with cash on Lantheus’ balance sheet and committed financing. , [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. , [18 F]-DCFPyL was approved by the FDA in May of 2021 and is commercially available as PYLARIFY ® (Piflufolastat F 18 Injection) and sold by Lantheus. PET/CT. PYLARIFY seems to be affected by the amount (level) of PSA in your blood. Customer Support at 1-800-964-0446 M-F 8:30 am-8:00 pm EST, or email cspyl@lantheus. Lantheus Holdings, Inc. 8 million for the first quarter 2023, representing an increase of 44. 48 from the prior year period. As part of the agreement with Novartis, Lantheus will provide PYLARIFY for the selection of patients with prostate cancer and Novartis will provide all PYLARIFY related clinical imaging data to Lantheus. The Company’s worldwide revenue for the third quarter of 2022 totaled $239. 97 for the first quarter of 2022, representing an increase of approximately $0. Lantheus Reports First Quarter 2023 Financial Results. This was another terrific quarter for Lantheus. 3 million for the third quarter 2022, representing an increase of 134. Further support is available from your local Lantheus account manager or the PYLARIFY® Reimbursement Hotline. The stock has been outperforming its index, the S&P Midcap 400, by a wide margin. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative. PYLARIFY Injection is designed to detect prostate-specific membrane. Mid-cap Lantheus Holdings has been on a revenue growth spurt boosted by a new product called Pylarify, which helps detect prostate cancer in an imaging test. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden. News release. 17%. PYLARIFY is the first and only commercially available, FDA-approved PSMA-targeted PET imaging agent for prostate cancer NORTH BILLERICA, Mass. 7 million, compared with $101. The company believes the approval of a PSMA-targeted therapeutic for the treatment of adult patients with PSMA-positive metastatic castration. distributor of PYLARIFY AI™, the first and only FDA-cleared artificial intelligence platform developed to assist standardized quantification of PSMA PET/CT scans. GAAP fully diluted earnings per share were $1. (NASDAQ:NASDAQ:LNTH) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ETCompany ParticipantsMark Kinarney - VP, IRMary. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET. 3% over the prior. 2023 Annual Scan Potential Estimates 12. net sales generated by PYLARIFY in 2022 and 2023 in excess of $100. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. (the Company) (NASDAQ: LNTH), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following presentations at. and Progenics Pharmaceuticals, Inc. Lantheus presented study results providing independent validation of PYLARIFY AI™, the Company’s artificial intelligence (AI) platform developed to assist in standardized quantification of PSMA PET/CT scans. 0% from the prior year period. 2 million, compared with $129. The Company’s worldwide revenue for the fourth quarter of 2022 totaled $263. --(BUSINESS WIRE)--May 27, 2021-- Lantheus Holdings, Inc. by year. Melissa Downs Senior Director, Corporate Communications 646. , Progenics Pharmaceuticals, Inc. Lantheus Holdings, Inc. Develop and deploy marketing strategies to drive ROI, sales and margin. This other product, even though it was, I'll say, riding the wave of the momentum that. Lantheus Holdings, Inc. PYLARIFY success leads to maximum payment in first yearBEDFORD, Mass. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. GAAP net loss. In. Contacts: Mark Kinarney Vice President, Investor Relations978-671-8842 [email protected] will provide further details on the PYLARIFY launch to date in a few minutes, but I am thrilled that less than one year after we commenced our launch, more than 30,000 men have been imaged. Lantheus Announces Presentation Featuring PYLARIFY® (Piflufolastat F18) at the 2022 ASCO GU Meeting. June 12, 2023 at 8:30 AM EDT. Customer Service: 1-800-299-3431: Hours: 7:30 a. • Visually inspect the radiopharmaceutical solution. 47, as compared to $0. Enrollment and participation is free, and does not impose any requirements on the manner in which the facility provides service to patients. In the U. S. , a Lantheus company 331. (the Company) ( NASDAQ: LNTH ), a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, announced it will present the following. 3 million for the third quarter 2022, representing an increase of 134. The Company’s worldwide revenue for the second quarter of 2022 totaled $223. PYLARIFY AI is an FDA-cleared medical device software and is commercially available in the United States. But most. The Company’s first quarter 2023 adjusted fully diluted net income per share, or earnings per share (“EPS”), was $1. MarketBeat Follows Only 4 people have added Lantheus to their MarketBeat. Using PYLARIFY AI™ to locate PSMA-avid lesions and track changes over time, investigators were able to determine that the change in the automated PSMA scan. NORTH BILLERICA, Mass. Apart from PYLARIFY’s impressive performance, Lantheus Holdings boasts a robust product portfolio with the potential for double-digit growth. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. 7% year-over-year growth and approximately 8% sequential growth from the first quarter of 2023. Lantheus’ product, PYLARIFY, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. 22, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY was approved by the U. Lantheus Holdings markets a fluorine-18 (F18) PSMA PET imaging product called Pylarify, for instance, which was approved last year. INDICATION. 29, 2021 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. November 29, 2021 08:30 ET | Source: Lantheus Holdings, Inc. (LNTH) 1 Like. The problem for Point, a group that went public amid much fanfare as a Spac last year, is that investors. 47, as compared to $0. Piflufolastat F 18 (PYLARIFY®) is an 18F-labelled diagnostic imaging agent that has been developed by Progenics Pharmaceuticals Inc. Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging agent for the detection of suspected recurrent or metastatic prostate cancer; TechneLite ® (Technetium Tc99m Generator), a. PYLARIFY® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men. Read More. S. S. Phone: 1-800-964-0446. Lantheus to Host Third Quarter 2023 Earnings Conference Call and Webcast on November 2, 2023, at 8:00 a. PYLARIFY Injection is designed to detect prostate-specific membrane. 96 and $0. . Those with suspected metastasis who are candidates for initial definitive therapy or those with suspected recurrence based on elevated. PYLARIFY may be diluted with 0. Worldwide revenue of $208. S. 50 from the prior year period. 00. S. PYLARIFY is the only PSMA-imaging agent that is widely available through a diverse, multi-partner F18 distributor network, ensuring convenient and reliable supply MARKET ACCESS More than 90% of covered lives have access to PSMA PET with PYLARIFY1 UTILIZATION PYLARIFY is the #1 ordered PSMA PET imaging agent in the U. We accelerated our growth. S. It is used to determine the presence or absence of recurrent or metastatic prostate cancer. S. Worldwide revenue of $263. PYLARIFY, AZEDRA, DEFINITY/LUMINITY, Xenon-133, NEUROLITE, TechneLite, Cardiolite, developmental products: United States. m.